| Nov 13 |
We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully
|
| Nov 8 |
Rezolute GAAP EPS of -$0.22
|
| Nov 7 |
Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
|
| Oct 17 |
With 62% ownership, Rezolute, Inc. (NASDAQ:RZLT) boasts of strong institutional backing
|
| Sep 19 |
Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
|
| Sep 9 |
Rezolute rises as FDA lifts clinical hold on hyperinsulinism therapy
|
| Sep 9 |
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
|
| Sep 3 |
Pleasing Signs As A Number Of Insiders Buy Rezolute Stock
|
| Aug 27 |
Rezolute to Participate in Upcoming Investor Conferences
|
| Aug 5 |
Rezolute gets FDA okay for Phase 3 ersodetug registrational study
|
